2022 World Conference on Lung Cancer (ePosters)-EP08.02-088. Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients

EP08.02-088. Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients

Back to course

Pdf Summary

A retrospective study was conducted on patients with non-small cell lung cancer who were treated with antiangiogenic agents. The study aimed to establish a relationship between the presence of tumor mutations and the response to these agents. The study included 16 patients, with a male to female ratio of 3:1 and an average age of 53 years. The most frequently used antiangiogenic drugs were bevacizumab and nintedanib. Molecular profiling revealed TP53, STK11, and KRAS as the most common mutations.<br /><br />The researchers evaluated the progression-free survival (PFS) during antiangiogenic therapy based on these mutations. It was found that patients with KRAS mutations had a shorter median PFS compared to those with KRAS wild-type. In contrast, patients with STK11 mutations had a longer median PFS compared to those with STK11 wild-type. However, these differences were not statistically significant. Patients with CDKN2A mutations had a shorter median PFS compared to those with CDKN2A wild-type, but again, the difference was not statistically significant.<br /><br />The study suggests that patients with mutations in CDKN2A and STK11 and KRAS wild-type may have longer PFS when treated with antiangiogenic agents, but further studies with larger sample sizes are needed to confirm these findings.<br /><br />Overall, the study provides insights into the potential use of specific genetic mutations as predictors of response to antiangiogenic therapy in non-small cell lung cancer patients. However, more research is required to validate these findings.

Asset Subtitle

Laura Gutiérrez Sainz

Meta Tag

Speaker Laura Gutiérrez Sainz

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective study

non-small cell lung cancer

antiangiogenic agents

tumor mutations

response

bevacizumab

nintedanib

progression-free survival

genetic mutations

predictors